SteadyMD
Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.
SteadyMD announced a $25 million Series B raise in March 2021.
Also: SteadyMD lands $25M for telemedicine platform and Lifelink System closes Series A round.
The raise will help SteadyMD further develop its technology platform and online services.
Primary care concierge platform SteadyMD just announced that it secured $2.